HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Lewy body disease — Clinical Guidelines

Overview

Lewy body disease encompasses both Parkinson disease (PD) and dementia with Lewy bodies (DLB), characterized by the presence of Lewy bodies in brain tissue, leading to a spectrum of motor, cognitive, and psychiatric symptoms. 1 2

Diagnosis

Key Diagnostic Criteria: Presence of Lewy bodies confirmed through alpha-synuclein immunohistochemistry.

Recommended Tests: Brain imaging (e.g., MRI) to rule out other causes; cerebrospinal fluid analysis may be considered but lacks specificity.

Neuropathological Confirmation: Essential for definitive diagnosis, focusing on alpha-synuclein pathology. 2

Management

First-Line Treatments:

- Motor Symptoms: Levodopa, dopamine agonists (e.g., pramipexole, ropinirole). - Cognitive and Psychiatric Symptoms: Cholinesterase inhibitors (e.g., donepezil, rivastigmine) for cognitive decline.

Adjunctive Treatments:

- Psychotic Symptoms: Clozapine for severe cases, particularly when other antipsychotics are ineffective or contraindicated. 3

Special Populations

Pregnancy: Rare cases of diffuse Lewy body disease onset post-partum noted, highlighting the unusual presentation in young adults. 4

Elderly: High rates of suboptimal hospice use observed, emphasizing the need for improved end-of-life care planning. 1

Key Recommendations

Utilize Uniform Immunohistochemical Methods for Diagnosis to enhance consistency in detecting Lewy body pathology across laboratories. (Evidence: Moderate) 2

Consider Clozapine for Severe Psychotic Symptoms in patients with diffuse Lewy body disease unresponsive to conventional antipsychotics. (Evidence: Weak) 3

Enhance Hospice Care Integration for elderly patients with Lewy body disease to reduce short hospice stays and improve quality of end-of-life care. (Evidence: Moderate) 1

References

1 Bock M, Gan S, Aldridge M, Harrison KL, Yaffe K, Smith AK et al.. Hospice Use Among Medicare Beneficiaries With Parkinson Disease and Dementia With Lewy Bodies. JAMA network open 2025. link 2 Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW et al.. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta neuropathologica 2008. link 3 Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. The Journal of neuropsychiatry and clinical neurosciences 1993. link 4 Opeskin K, Gonzales M, Borenstein R, Anderson R. Diffuse Lewy body disease with immediate post-partum onset. Acta neuropathologica 1993. link

Lewy body disease